RxDoctor Payments DataLook up a doctor →

Jared Cox, MD

Urology · Homewood, ALNPI 1942410386

Payments from drug & device makers

$11,536in general payments, 2019–2025

Across 425 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Ferring Pharmaceuticals Inc.$2K
  • Neotract Inc.$1K
  • Sumitomo Pharma America, Inc.$1K
  • Astellas Pharma US Inc$576
  • Johnson & Johnson$454
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$1,58014%
  • Travel & lodging$1,0729%
  • Food & beverage$8,57774%
  • Education$3073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,536 in reported general payments places this provider in the 75th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$204,448
Medicare patients
547
Services billed
14,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix33$88,805
MyrbetriqMirabegron93$54,555
GemtesaVibegron64$44,673
Tamsulosin Hcl904$13,014
Oxybutynin Chloride ErOxybutynin Chloride264$7,572
Potassium Citrate ErPotassium Citrate42$3,269
Finasteride246$3,236
Testosterone Cypionate89$2,515
Silodosin25$2,270
Testosterone15$1,967
NitrofurantoinNitrofurantoin Macrocrystal23$1,186
Estradiol11$1,013
Alfuzosin Hcl ErAlfuzosin Hcl30$711
Dutasteride21$453
Oxybutynin Chloride23$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,174$133,47897 claims
Astellas Pharma US IncMyrbetriq$576$54,55593 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 179 urology providers in Alabama.

Other urology in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →